Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

Ryuta Uraki,Shun Iida,Peter J. Halfmann,Seiya Yamayoshi,Yuichiro Hirata,Kiyoko Iwatsuki-Horimoto,Maki Kiso,Mutsumi Ito,Yuri Furusawa,Hiroshi Ueki,Yuko Sakai-Tagawa,Makoto Kuroda,Tadashi Maemura,Taksoo Kim,Sohtaro Mine,Noriko Iwamoto,Rong Li,Yanan Liu,Deanna Larson,Shuetsu Fukushi,Shinji Watanabe,Ken Maeda,Zhongde Wang,Norio Ohmagari,James Theiler,Will Fischer,Bette Korber,Masaki Imai,Tadaki Suzuki,Yoshihiro Kawaoka
DOI: https://doi.org/10.1038/s41467-023-37059-x
IF: 16.6
2023-03-23
Nature Communications
Abstract:Abstract The prevalence of the Omicron subvariant BA.2.75 rapidly increased in India and Nepal during the summer of 2022, and spread globally. However, the virological features of BA.2.75 are largely unknown. Here, we evaluated the replicative ability and pathogenicity of BA.2.75 clinical isolates in Syrian hamsters. Although we found no substantial differences in weight change among hamsters infected with BA.2, BA.5, or BA.2.75, the replicative ability of BA.2.75 in the lungs is higher than that of BA.2 and BA.5. Of note, BA.2.75 causes focal viral pneumonia in hamsters, characterized by patchy inflammation interspersed in alveolar regions, which is not observed in BA.5-infected hamsters. Moreover, in competition assays, BA.2.75 replicates better than BA.5 in the lungs of hamsters. These results suggest that BA.2.75 can cause more severe respiratory disease than BA.5 and BA.2 in a hamster model and should be closely monitored.
multidisciplinary sciences
What problem does this paper attempt to address?